China SXT Pharmaceuticals (SXTC) Common Equity: 2018-2025
- China SXT Pharmaceuticals' Common Equity rose 247.50% to $116.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.0 million, marking a year-over-year increase of 247.50%. This contributed to the annual value of $15.4 million for FY2025, which is 10.83% up from last year.
- China SXT Pharmaceuticals' Common Equity amounted to $116.0 million in Q3 2025, which was up 651.49% from $15.4 million recorded in Q1 2025.
- Over the past 5 years, China SXT Pharmaceuticals' Common Equity peaked at $116.0 million during Q3 2025, and registered a low of $13.9 million during Q1 2024.
- In the last 3 years, China SXT Pharmaceuticals' Common Equity had a median value of $24.4 million in 2024 and averaged $38.2 million.
- Its Common Equity has fluctuated over the past 5 years, first dropped by 10.55% in 2023, then surged by 247.50% in 2025.
- China SXT Pharmaceuticals' Common Equity (Quarterly) stood at $26.0 million in 2021, then grew by 23.85% to $32.2 million in 2022, then grew by 11.60% to $35.9 million in 2023, then decreased by 7.12% to $33.4 million in 2024, then surged by 247.50% to $116.0 million in 2025.
- Its Common Equity stands at $116.0 million for Q3 2025, versus $15.4 million for Q1 2025 and $33.4 million for Q3 2024.
